Merck KGaA said its doors are open for more M&A, particularly for its manufacturing business, as the company tempers sales ...

BenevolentAI's CEO Joerg Moeller is stepping down effective immediately, the London biotech said Thursday, in the latest ...

Avadel Pharmaceuticals said its once-nightly narcolepsy drug Lumryz can now be used to treat children older than 7 years of ...

Australia’s regulatory agency rejected Biogen and Eisai’s Alzheimer’s drug Leqembi, noting that the drug's efficacy doesn't ...

CDMO OmniaBio on Thursday opened a commercial-stage cell manufacturing facility that has AI capabilities worth around CAD ...

After a string of mid-stage failures this year, plus a blow to its major depression commercial plans last year, Sage ...

Novartis is spending $70 million upfront on a small molecule antitumor drug from the Chinese biotech Chengdu Baiyu. The Swiss ...

Plus, news about Kezar Life Sciences and Concentra Biosciences: Viatris, Lexicon Pharmaceuticals sign licensing deal for cardio drug: Per the agreement, Viatris will pay $25 million ...

A month after making a foray into the bustling radioligand field, Sanofi is further allying itself with Orano Med, paying ...

Bavarian Nordic’s mpox vaccine Jynneos generated a similar immune response in adolescents as it did in adults, offering ...

The Alliance for Pharmacy Compounding (APC) wants clarity around the FDA’s decision to reconsider tirzepatide’s removal from ...

An experimental therapy designed to change a single letter of short-lived mRNA molecules has corrected a genetic mutation ...